DIAMEDICA THERAPEUTICS INC.
SCIENTIFIC AND CLINICAL RESEARCH COMMITTEE CHARTER

Organization

The Scientific and Clinical Research Committee (the "Committee") is a standing committee of the Board of Directors (the "Board") of DiaMedica Therapeutics Inc. (the "Company"). This charter will govern the operations of the Committee.

Purpose and Authority

The primary purpose of the Committee is to assist the Board by providing advice, understanding and guidance, both to management of the Company and the Board, regarding:

- understanding the scientific, state-of-the-art and emerging science and technology trends of the global medical applications of current or proposed product candidates that the Company is pursuing or plans to pursue;
- an understanding of and providing guidance on the early- and late-stage clinical research plans, and clinical trial and publication strategies of the Company; and
- providing advice on interactions with regulatory bodies, especially the U.S. Food and Drug Administration, clinical principal investigators and clinical trial committees, and any employed contract research organizations ("CROs").

The Committee has the power and authority to retain or obtain the advice of consultants, legal counsel or other advisers and will have the sole authority to select, retain, oversee and terminate such consultants, counsel and advisors and approve the fees and other retention terms of such consultants, counsel and advisors, as it deems appropriate. The Company will provide adequate and appropriate funding, as determined by the Committee, for payment of reasonable compensation to any such adviser retained by the Committee and to fund other ordinary administrative expenses that are necessary or appropriate for the Committee in carrying out its responsibilities.

Membership and Structure

The Committee will consist of at least three directors. The Company's Chief Medical Officer will serve as the Committee's Secretary and a liaison between the Committee and management. Each Board member of the Committee will be an "independent director" within the meaning of the Listing Rules of the Nasdaq Stock Market. The Board will be responsible for determining whether a Committee member is an "independent director." Notwithstanding the foregoing, the Board may decide at any time and in its sole discretion to waive the foregoing qualification with respect to a member of the Committee for a transitional time period if then permitted under applicable laws, rules and regulations.

Appointment to the Committee, including the designation of the Chair of the Committee, will be made on an annual basis by the full Board. Committee members will serve until their successors are appointed and qualify. Committee members may be removed by the Board at any time. The Chair of the Committee will report on activities of the Committee to the full Board.

Meetings of the Committee will be held at such times and places as the Committee will determine, including by written consent. The Committee may invite members of management or other advisors to attend meetings and provide pertinent information. When necessary, the Committee will meet in executive session outside of the presence of any senior executive officer of the Company, including the Chief Medical Officer.

In fulfilling its responsibilities, the Committee will have authority to delegate its authority to subcommittees, in each case to the extent permitted by applicable law.

Duties and Responsibilities

The Committee will have the power and authority of the Board to perform the following duties and to fulfill the following responsibilities:

- Review with the Company the existing medical and scientific, state of the art, diagnostic and therapeutic trends for medical conditions that the Company is pursuing or plans to pursue.

- Review with, and assist when necessary, management in early- and late-stage clinical research and clinical trial plans and strategies, including statistical plans for group sequential analysis and/or adaptive clinical trials designs and identifying scientific advisory board members.

- Review with management the external clinical research structures, including any CROs, and critical adjudication committee membership and structure for current or planned clinical studies.

- Review clinical research results to evaluate product cost-effectiveness and understand reimbursement strategies.

- Review periodically ongoing clinical research and clinical trial progress.

- Review and provide guidance on publication strategies of the Company.
- Provide advice on interactions with regulatory bodies, especially the FDA, clinical principal investigators and clinical trial committees, and any employed CROs.
- Provide summaries and guidance to the Board regarding the Committee's scientific and clinical research meeting activities.

Approved by the
Board of Directors of DiaMedica Therapeutics Inc.:
May 22, 2024